BRAF突变转移性结直肠癌的治疗选择与循证指南综述
本文综述BRAF V600E突变在转移性结直肠癌(mCRC)发病机制、预后及疗效预测中的作用,并汇总当前循证治疗推荐。BRAF突变见于约10%的mCRC患者,提示预后不良。一线标准治疗包括化疗联合贝伐珠单抗,体能状态良好者可选用FOLFOXIRI联合贝伐珠单抗;MAPK通路阻断联合策略(如encorafenib联合西妥昔单抗)已获BEACON CRC研究支持。
要点
- BRAF V600E突变见于约10%的mCRC患者,是预后不良标志。
- 一线标准治疗为化疗联合贝伐珠单抗,体能良好者可用FOLFOXIRI联合贝伐珠单抗。
- BEACON CRC研究支持encorafenib联合西妥昔单抗用于BRAF V600E突变mCRC。
核心结论
- BRAF突变mCRC的治疗近年快速发展,MAPK通路阻断联合策略显示 promising 结果,其他潜在靶点仍在探索。
研究设计与样本
- 本文为综述,回顾BRAF V600E突变在mCRC发病机制、预后标志及疗效预测中的临床与转化文献,并总结循证管理推荐。
主要发现
- BRAF V600E突变发生于约10%的mCRC患者,是预后不良标志。
- 一线标准治疗包括化疗联合贝伐珠单抗,以及体能状态良好者采用FOLFOXIRI联合贝伐珠单抗。
- BEACON CRC研究是迄今该人群最大研究,为encorafenib联合西妥昔单抗抑制BRAF和EGFR提供强临床证据。
关键数值与推荐
- BRAF突变见于约10%的mCRC患者。
- 一线标准治疗:化疗联合贝伐珠单抗;体能状态良好者可用FOLFOXIRI联合贝伐珠单抗。
- BEACON CRC研究支持encorafenib联合西妥昔单抗用于BRAF V600E突变mCRC。
临床怎么用
- mCRC患者应检测BRAF V600E突变以评估预后。
- 体能状态良好者一线可考虑FOLFOXIRI联合贝伐珠单抗。
- BRAF V600E突变mCRC可考虑encorafenib联合西妥昔单抗的MAPK通路阻断策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Colorectal cancer (CRC) is still a leading cause of cancer-related deaths in the United States and worldwide, despite recent improvements in cancer management. CRC, like many malignancies, is a heterogeneous disease, with subtypes characterized by genetic alterations. One common mutation in CRC is in the BRAF gene (most commonly V600E substitution). This occurs in ∼10% of patients with metastatic CRC (mCRC) and is a marker of poor prognosis. DESIGN: Herein, we review the clinical and translational literature on the role of the BRAF V600E mutation in the pathogenesis of mCRC, its mechanisms as a prognostic marker, and its potential utility as a predictive marker of treatment response. We then summarize the current evidence-based recommendations for management of BRAF V600E-mutated mCRC, with a focus on recent clinical research advances in this setting. RESULTS: The current standard therapies for first-line treatment of BRAF-mutated mCRC are chemotherapy with bevacizumab as well as 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab in patients with a good performance status. Combination strategies involving mitogen-activated protein kinase (MAPK) pathway blockade have shown promising results for the treatment of patients with BRAF V600E-mutated mCRC. The Binimetinib, Encorafenib, And Cetuximab cOmbiNed to treat BRAF-mutant ColoRectal Cancer (BEACON CRC) study represents the largest study in this population to date and has given strong clinical evidence to support BRAF and epidermal growth factor receptor inhibition with the combination of encorafenib plus cetuximab. CONCLUSIONS: The treatment of BRAF-mutated mCRC has evolved rapidly over the last several years. Recently, combination strategies involving MAPK pathway blockade have shown promising results in BRAF V600E-mutated mCRC, and other potential targets continue to be explored. In addition, a greater understanding of the role of BRAF V600E mutation in the pathogenesis of CRC should also continue to fuel advances in the management of patients with mCRC harboring this genetic aberration.
引用
- Grothey A, Fakih M, Tabernero J, et al. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines. Ann Oncol. 2021. PMID: 33836264. doi:10.1016/j.annonc.2021.03.206
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。